Balkonnect Festival 2025 - B2B Matchmaking Event

23–24 May 2025 | Prishtina, Kosovo

ProductUpdated on 9 April 2025

LIQUID VITAMIN D3 (Cholecalciferol)

Federico Ponchiroli

Product manager at O.P. Pharma Srl

Milan, Italy

About

Cholecalciferol is Vitamin D3, which is naturally produced in the body after exposure to sunlight and is indicated for prevention and treatment of Vitamin D Deficiency as well as adjunct to specific therapy for osteoporosis. Vitamin D deficiency in children can manifest as rickets, while in adults results in osteomalacia; the recommended treatment regimen is usually based on fixed loading doses followed by regular maintenance therapy.

OP Pharma developed since 2012, registered and marketed in the EU since 2015 under various brands its own all-natural, high-dose liquid Vitamin D formulation: it's simple but effective since it contains Cholecalciferol and one only excipient, olive oil, which are well known substances; no other excipients are added to the oily solution thus leading to a simple formulation, without any added antioxidant, preservatives or other additives. It's also gluten/lactose/alcohol-free.

It is available in 2 dosage forms: Oral drops and Oral solution: this enables the administration to all populations.

For each of the 2 dosage forms, 2 strengths are available: 10,000IU/mL and 20,000IU/mL: this enhances product adherence to various posologies and makes it easy to calculate the correct dose to be prescribed and administered.

Oral drops are packaged in a 10mL presentation with inserted dropper, while monodose Oral solution in 2,5mL presentation; both are packaged in glass bottles/vials and closed by tamper-proof capsule (Oral drops presentation is also child-proof). Either Oral drops and Oral solution presentations can be packaged in multiple packs containing from 1 to 2, 4 ... 10 bottles/vials (other packs may be evaluated and developed according to specific needs).

All packs are “made-in-Italy” and manufactured by CMOs having a long-term business relationship with OP Pharma. The dossier is EU-approved in eCTD format; stability data are available up to 24 months even in IVb conditions.

Similar opportunities